A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b

Phase 2

• Conditions: Multiple Myeloma
• Interventions: Drug: Darinaparson

• Registration Number: NCT00423644
• Lead Sponsor: Alaunos Therapeutics

Brief Summary

The study of safety of a new organic arsenic compound in the treatment of advanced multiple myeloma

Detailed Description

Not available

Study Timeline

• Study Start: 2007-01
• Study First Submitted: 2007-01-16
• Study First Submitted QC: 2007-01-17
• Study First Posted: 2007-01-18
• Status Verified: 2013-11
• Last Update Submitted: 2013-11-13
• Last Update Posted: 2013-11-14
• Primary Completion: 2013-12
• Study Completion: 2013-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 17

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Single Arm	Darinaparson	-

Primary Outcome Measures

Name	Time	Method
Response Rate	6 months

Secondary Outcome Measures

Name	Time	Method
Survival (overall and progression free)	6 months
toxicities	6 months